Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest cancer types due to it aggressiveness and difficulty in obtaining early diagnosis. Furthermore, one of the main reasons for high mortality rates is resistance to conventional therapies, such as chemotherapy. The KRAS gene is frequently mutated in PDAC and is considered a potential therapeutic target. Recently, some KRAS inhib…